يعرض 821 - 840 نتائج من 34,836 نتيجة بحث عن '(( 50 ((a decrease) OR (mean decrease)) ) OR ( e ((fold decrease) OR (point decrease)) ))', وقت الاستعلام: 0.96s تنقيح النتائج
  1. 821
  2. 822
  3. 823
  4. 824
  5. 825

    New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres حسب Mohamed I. Attia (2392672)

    منشور في 2017
    "…In addition, compound <b>7e</b> increased phosphorylated tyrosine (p-Tyr) levels nearly two-fold with an apparent IC<sub>50</sub> value of 3.8 μM. …"
  6. 826

    Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. حسب David W. Donley (3111198)

    منشور في 2021
    "…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …"
  7. 827
  8. 828

    Heatmap of fold-changes of metabolites. حسب Elena Heidenreich (6940475)

    منشور في 2019
    "…HL, i.e., 50 vs. 300 μmol photons m<sup>-2</sup> s<sup>-1</sup>) for diploid (2N) and haploid (1N) <i>E</i>. …"
  9. 829

    Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study حسب Jon Jarløv Rasmussen (2993427)

    منشور في 2016
    "…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …"
  10. 830
  11. 831

    Annual number of outpatient visits in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"
  12. 832

    Annual treatment frequencies in all eyes. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"
  13. 833

    Annual number of outpatient visits in all eyes. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"
  14. 834
  15. 835

    Annual treatment frequencies in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"
  16. 836
  17. 837
  18. 838
  19. 839
  20. 840